SOURCE: Five Star Equities

Five Star Equities

August 21, 2012 08:20 ET

Favorable Legislation and a Flurry of M&A Activity Have Been Contributing Factors to Biotech Industry's Success in 2012

Five Star Equities Provides Stock Research on Pluristem Therapeutics and Neostem

NEW YORK, NY--(Marketwire - Aug 21, 2012) - Biotechnology stocks continue to be some of the strongest performers in the markets as favorable legislation, such as the FAST and TREAT acts, have helped boost investor optimism within the industry. The iShares Nasdaq Biotechnology Index Fund is up over 28 percent in 2012 -- handedly outperforming the Dow Jones industrial average year-to-date. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Pluristem Therapeutics Inc. (NASDAQ: PSTI) and Neostem Inc. (NYSE: NBS).

Access to the full company reports can be found at:

www.FiveStarEquities.com/PSTI
www.FiveStarEquities.com/NBS

The FAST and TREAT acts introduced in 2012 have helped accelerate the development, review and approval process of medicines/personalized therapies for patients suffering from serious and life-threatening diseases. According to recent data from Thomas Reuters, biotech mergers & acquisitions activity is currently at a four-year high as large pharmaceuticals are facing major patent cliffs. So far in 2012 the volume of biotech M&A has exceeded $25 billion, compared to roughly 10 billion in the same period of 2011.

"Their patents have expired, and as a result they have holes in their revenue line they are trying to fill," said Scott Lindsay, global head of mergers and acquisitions at Credit Suisse. "The other part is just shoring up the pipeline they have. So even if they don't have a major patent problem, they're all looking for growth."

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Pluristem Therapeutics is a leading developer of standardized cell therapy products for the treatment of life threatening diseases. The company's patented PLX cells drug delivery platform releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory diseases. The company recently received permission from the Indian Ministry of Health to proceed with a Phase II clinical trial for the treatment of thromboangiitis obliterans (Buerger's disease).

NeoStem continues to develop and build on its core capabilities in cell therapy to capitalize on the paradigm shift that they see occurring in medicine. The company recently reported that on August 9, 2012 it received approval to continue its PreSERVE AMI Phase 2 clinical trial following its first interim data and safety review by the Data Safety Monitoring Board (DSMB).

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at: www.FiveStarEquities.com/disclaimer

Contact Information